RXRX RECURSION PHARMACEUTICALS IN revenue, earnings and financials

For the quarter ended June 30, 2026, RECURSION PHARMACEUTICALS IN reported revenue of $7.67M (down 60.1% from a year earlier), net income of −$131M and diluted EPS of −$0.25; over the last four quarters revenue was $54.9M and net income −$519M; for the fiscal year ended December 2025 revenue was $74.7M, up 26.9% on the year before.

RXRX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $74.7M, gross profit n/a, operating income −$648M, net income −$645M (margin -863.4%), EPS −$1.44
• Fiscal year ended Dec 2024: revenue $58.8M, gross profit n/a, operating income −$479M, net income −$464M (margin -788.0%), EPS −$1.69
• Fiscal year ended Dec 2023: revenue $44.6M, gross profit n/a, operating income −$350M, net income −$328M (margin -736.0%), EPS −$1.58
• Fiscal year ended Dec 2022: revenue $39.8M, gross profit n/a, operating income −$246M, net income −$239M (margin -601.0%), EPS −$1.36
• Fiscal year ended Dec 2021: revenue $10.2M, gross profit n/a, operating income −$183M, net income −$186M (margin -1832.2%), EPS −$1.49

RXRX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $7.67M (down 60.1% year over year), net income −$131M, EPS −$0.25
• Quarter ended Mar 31, 2026: revenue $6.47M (down 56.1% year over year), net income −$118M, EPS −$0.22
• Quarter ended Dec 31, 2025 (from the annual report): revenue $35.5M (up 681.7% year over year), net income −$108M, EPS −$0.17
• Quarter ended Sep 30, 2025: revenue $5.18M (down 80.2% year over year), net income −$162M, EPS −$0.36
• Quarter ended Jun 30, 2025: revenue $19.2M (up 33.3% year over year), net income −$172M, EPS −$0.41
• Quarter ended Mar 31, 2025: revenue $14.7M (up 6.9% year over year), net income −$202M, EPS −$0.50
• Quarter ended Dec 31, 2024 (from the annual report): revenue $4.55M (down 58.3% year over year), net income −$179M, EPS −$0.56
• Quarter ended Sep 30, 2024: revenue $26.1M (up 147.6% year over year), net income −$95.8M, EPS −$0.34
• Quarter ended Jun 30, 2024: revenue $14.4M (up 30.9% year over year), net income −$97.5M, EPS −$0.40
• Quarter ended Mar 31, 2024: revenue $13.8M (up 13.7% year over year), net income −$91.4M, EPS −$0.39
• Quarter ended Dec 31, 2023 (from the annual report): revenue $10.9M (down 20.4% year over year), net income −$93.0M, EPS −$0.43
• Quarter ended Sep 30, 2023: revenue $10.5M (down 20.0% year over year), net income −$93.0M, EPS −$0.43
• Quarter ended Jun 30, 2023: revenue $11.0M (up 43.6% year over year), net income −$76.7M, EPS −$0.38
• Quarter ended Mar 31, 2023: revenue $12.1M (up 127.5% year over year), net income −$65.3M, EPS −$0.34
• Quarter ended Dec 31, 2022 (from the annual report): revenue $13.7M (up 439.9% year over year), net income −$57.5M, EPS −$0.30
• Quarter ended Sep 30, 2022: revenue $13.2M (up 419.3% year over year), net income −$60.4M, EPS −$0.35
• Quarter ended Jun 30, 2022: revenue $7.67M (up 201.1% year over year), net income −$65.6M, EPS −$0.38
• Quarter ended Mar 31, 2022: revenue $5.33M (up 108.2% year over year), net income −$56.0M, EPS −$0.33
• Quarter ended Dec 31, 2021 (from the annual report): revenue $2.53M, net income −$64.9M, EPS $0.43
• Quarter ended Sep 30, 2021: revenue $2.53M, net income −$47.4M, EPS −$0.28

RXRX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$372M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$359M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$288M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$83.5M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$159M, share buybacks n/a

RXRX balance sheet

• Jun 30, 2026: cash $546M, total assets $1.21B, total liabilities $298M, shareholders' equity $915M
• Mar 31, 2026: cash $654M, total assets $1.34B, total liabilities $315M, shareholders' equity $1.02B
• Dec 31, 2025: cash $743M, total assets $1.47B, total liabilities $343M, shareholders' equity $1.13B
• Sep 30, 2025: cash $660M, total assets $1.40B, total liabilities $353M, shareholders' equity $1.05B
• Jun 30, 2025: cash $525M, total assets $1.30B, total liabilities $383M, shareholders' equity $919M
• Mar 31, 2025: cash $500M, total assets $1.31B, total liabilities $371M, shareholders' equity $934M
• Dec 31, 2024: cash $594M, total assets $1.45B, total liabilities $414M, shareholders' equity $1.03B
• Sep 30, 2024: cash $428M, total assets $726M, total liabilities $202M, shareholders' equity $525M

What is RXRX's revenue?

RECURSION PHARMACEUTICALS IN reported $54.9M of revenue over its last four quarters, through June 30, 2026.

Is RXRX profitable?

No. RECURSION PHARMACEUTICALS IN lost $519M over the last four quarters.

What is RXRX's EPS?

Diluted earnings per share over the last four quarters were −$1.00; −$0.25 in the latest quarter.

RXRX ownership and insider trades · All stocks